{"id":576045,"date":"2019-03-28T03:44:56","date_gmt":"2019-03-28T10:44:56","guid":{"rendered":"https:\/\/www.microsoft.com\/en-us\/research\/?post_type=msr-project&p=576045"},"modified":"2022-09-06T09:59:49","modified_gmt":"2022-09-06T16:59:49","slug":"assessing-multiple-sclerosis-with-kinect","status":"publish","type":"msr-project","link":"https:\/\/www.microsoft.com\/en-us\/research\/project\/assessing-multiple-sclerosis-with-kinect\/","title":{"rendered":"Assessing Multiple Sclerosis with Kinect"},"content":{"rendered":"
\t\t\t
Multiple Sclerosis is a neuro-degenerative condition that causes physical and cognitive impairment over an unpredictable timeframe, making the ability to detect disease change very important. Currently disease tracking is done through clinical examination, in which a neurologist watches a patient perform a number of exercises, such as touching the finger to the nose, and then rates the level of motor abnormality. However, the high variance in judgements between neurologists, or the same neurologist at different time points, makes reliably tracking disease progression problematic. The high variance in current tools requires large number of patients to be included in clinical trials, making the discovery and evaluation of new treatments a slow and expensive process.<\/p>
ASSESS MS addresses this by providing a consistent, quantified measure of motor ability using Kinect that is both inexpensive and non-invasive. Using Kinect, the system captures depth videos of neuro-assessment movements performed by patients in a clinical setting with the support of the health professional. The videos are then processed offline and a classification of specific aspects of motor ability is provided based on the Expanded Disability Severity Score (EDSS). These are then presented back to the health professional through a series of visualisations that compare data over time. The project is a collaboration between the Human Experience & Design group and the Machine Learning and Perception group at Microsoft Research Cambridge, as well as Novartis Pharma AG (Basel, Switzerland) and three large research hospitals in Europe (Basel, Bern, Amsterdam).<\/p>